Japanese hemophilia patients monitored on alhemo in new safety study
NCT ID NCT06285071
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks the safety and effectiveness of the drug Alhemo (concizumab) in 23 people with hemophilia A or B in Japan. Participants receive the drug as part of their normal care, and researchers will monitor side effects for about 2 years. The goal is to see how well Alhemo works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Concizumab (Alhemo)
What this could lead to
If successful, this study will confirm that Alhemo is safe and effective for routine use in people with hemophilia A or B in Japan.
What could go wrong
This is an observational study with only 23 participants, so results may not apply to everyone. It is not designed to prove new benefits, only to monitor real-world safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Occupational And Environmental Health Japan_Pediatrics
Kitakyusyu-shi, Fukuoka, 807 8555, Japan
-
Kagoshima City Hospital_Pediatrics
Kagoshima, 890-8760, Japan
-
Kyushu university hospital_Pediatrics
Fukuoka, 812-8582, Japan
-
Mutsu general hospital_Pediatrics
Aomori, 035-8601, Japan
-
Nanbu Medical Center & Children's Medical Center_Hematology and Oncology
Okinawa, 901-1193, Japan
-
Novo Nordisk Investigational Site
Toshima City, Tokyo, Japan
-
Ogikubo Hospital_Blood Coagulation
Tokyo, 167-0035, Japan
-
Sapporo Tokushukai Hospital_Pediatrics
Hokkaido, 004-0041, Japan
-
St. Marianna University School of Medicine Hospital_Pediatrics
Kanagawa, 216-8511, Japan
-
Tokyo Medical University Hospital
Tokyo, 160-0023, Japan
-
University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology
Okinawa, 901-2725, Japan